HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

TitleHIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Publication TypeJournal Article
Year of Publication2016
AuthorsSchoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JCC, Parrish EH, Learn GH, West AP, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath JM, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC
JournalScience
Volume352
Issue6288
Pagination997-1001
Date Published05/20/2016
ISSN1095-9203
Abstract

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.

DOI10.1126/science.aaf0972
Alternate JournalScience
PubMed ID27199429
Grant List1UM1 AI00645 / AI / NIAID NIH HHS / United States
1UM1 AI100663-01 / AI / NIAID NIH HHS / United States
AI045008 / AI / NIAID NIH HHS / United States
F30 AI112426 / AI / NIAID NIH HHS / United States
P01 AI100148 / AI / NIAID NIH HHS / United States
UM1AI068618 / AI / NIAID NIH HHS / United States
UM1AI069481 / AI / NIAID NIH HHS / United States
/ / Howard Hughes Medical Institute / United States
CHAVI-ID: 
1
Cover Picture: